Blanca Pharmaceuticals, LLC is dedicated to discovering and developing parenteral and oral carbacephem antibiotics for the improved treatment of serious human bacterial infections, including those caused by resistant Gram-positive and Gram-negative bacteria. The Company is focused exclusively on one development-stage parenteral carbacephem product, and one discovery-stage oral carbacephem program: * BP-102/Tazobactam, a parenteral, bactericidal fixed combination of a proprietary broad-spectrum carbacephem compound and a well-established beta-lactamase inhibitor, now in late-stage preclinical development. This product is designed for broad-spectrum empiric therapy in the hospital setting, having both a solid Gram-negative spectrum (including excellent activity against emerging strains of resistant Acinetobacter), and superb efficacy against todayâs most problematic Gram-positive pathogens, such as MRSA/E, GISA, PRSP and VRE. * An early, exploratory oral carbacephem program, seeking to discover an orally-active prodrug of BP-101 or BP-102, for primary use in the outpatient / community setting, and for in-hospital "step-down" therap
